Keep a close eye on Shire plc (SHPG) . The U.S. Food and Drug Administration (FDA) has expanded the approved uses of its Vyvanse(R) (lisdexamfetamine dimesylate)
SHPG's Vyvanse is a central nervous system stimulant prescription medicine approved in 2007 by the FDA for the treatment of Attention Deficit Hyperactivity Disorder. On Friday, the FDA cleared Vyvanse to treat binge-eating disorder in adults
Binge eating disorder is characterized by recurring episodes of compulsive overeating in which people consume larger amounts of food than normal while feeling out of control and powerless to stop. It is the most common eating disorder in the United States (more common than anorexia and bulimia combined), affecting an estimated 2.8 million adults, according to a national survey.
SHPG's Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) is the first and only FDA-approved medication for the treatment of moderate to severe binge eating disorder in adults, shown to significantly reduce the mean number of binge days per week.
SHPG is expected to report its fourth quarter and full year 2014 financial results on February 12, 2015
SHPG enables people with life-altering conditions to lead better lives. SHPG focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and the company is developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.
More about Shire plc (SHPG) at www.shire.com
**
Chimerix, Inc. (CMRX) reported that after discussion with the FDA, the company is ceasing further participation in all current and future clinical studies of brincidofovir for Ebola Virus Disease (EVD), including the study announced in December in Liberia sponsored by investigators at the University of Oxford and the supportive Phase 2 study of brincidofovir for EVD, Study 205.
According to CMRX, over the last several weeks the number of new cases of confirmed Ebola Virus Disease in Liberia has decreased significantly, with only a handful of patients enrolled to date in the single-arm study of brincidofovir.
CMRX said that it will continue to push forward with its development of brincidofovir for the prevention and treatment of serious viral infections in transplant recipients and other immunocompromised patients
CMRX is currently enrolling SUPPRESS, a Phase 3 study of brincidofovir for the prevention of cytomegalovirus in adult hematopoietic cell transplant recipients. In addition, CMRX is enrolling the Phase 3 AdVise trial of brincidofovir for treatment of adenovirus infection. CMRX is working with BARDA to develop brincidofovir as a medical countermeasure against smallpox.
CMRX is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need.
More about Chimerix, Inc. (CMRX) at www.chimerix.com.
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Roseville, CA ( www.roseville.crwe-pr.com ) into the CRWE Network.
Roseville is the largest city in Placer County, California. It is located 16 miles from Sacramento, the state capital. The strength and balance of Roseville’s diverse economy allows the city to thrive. Business ventures in Roseville range from technology, healthcare, agriculture and financial services.
The City of Roseville had an estimated population in 2013 (U.S. Census Bureau) of 127,035, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
SHPG's Vyvanse is a central nervous system stimulant prescription medicine approved in 2007 by the FDA for the treatment of Attention Deficit Hyperactivity Disorder. On Friday, the FDA cleared Vyvanse to treat binge-eating disorder in adults
Binge eating disorder is characterized by recurring episodes of compulsive overeating in which people consume larger amounts of food than normal while feeling out of control and powerless to stop. It is the most common eating disorder in the United States (more common than anorexia and bulimia combined), affecting an estimated 2.8 million adults, according to a national survey.
SHPG's Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) is the first and only FDA-approved medication for the treatment of moderate to severe binge eating disorder in adults, shown to significantly reduce the mean number of binge days per week.
SHPG is expected to report its fourth quarter and full year 2014 financial results on February 12, 2015
SHPG enables people with life-altering conditions to lead better lives. SHPG focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and the company is developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.
More about Shire plc (SHPG) at www.shire.com
**
Chimerix, Inc. (CMRX) reported that after discussion with the FDA, the company is ceasing further participation in all current and future clinical studies of brincidofovir for Ebola Virus Disease (EVD), including the study announced in December in Liberia sponsored by investigators at the University of Oxford and the supportive Phase 2 study of brincidofovir for EVD, Study 205.
According to CMRX, over the last several weeks the number of new cases of confirmed Ebola Virus Disease in Liberia has decreased significantly, with only a handful of patients enrolled to date in the single-arm study of brincidofovir.
CMRX said that it will continue to push forward with its development of brincidofovir for the prevention and treatment of serious viral infections in transplant recipients and other immunocompromised patients
CMRX is currently enrolling SUPPRESS, a Phase 3 study of brincidofovir for the prevention of cytomegalovirus in adult hematopoietic cell transplant recipients. In addition, CMRX is enrolling the Phase 3 AdVise trial of brincidofovir for treatment of adenovirus infection. CMRX is working with BARDA to develop brincidofovir as a medical countermeasure against smallpox.
CMRX is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need.
More about Chimerix, Inc. (CMRX) at www.chimerix.com.
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Roseville, CA ( www.roseville.crwe-pr.com ) into the CRWE Network.
Roseville is the largest city in Placer County, California. It is located 16 miles from Sacramento, the state capital. The strength and balance of Roseville’s diverse economy allows the city to thrive. Business ventures in Roseville range from technology, healthcare, agriculture and financial services.
The City of Roseville had an estimated population in 2013 (U.S. Census Bureau) of 127,035, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
